Merck Acquires Life Sciences Company Bio-Techne
Merck has agreed to acquire Bio-Techne in an all-cash deal valuing the company at approximately $11.3 billion.
The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through development, testing and commercial manufacturing. Additionally, it would directly deliver on Merck’s mid- to long-term strategic agenda, which focuses on high-growth value drivers, integrated workflows, platformed capabilities and scaling and sourcing innovation through M&A.
“This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and solutions across the entire industry value chain – from lab customers to those manufacturing in the biotech and pharmaceutical industries,” said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck. “By combining Bio-Techne’s scientific depth, innovation engine and differentiated portfolio with Merck’s global scale, manufacturing excellence and customer reach, we are in a strong position to address some of the most important opportunities in life sciences and support our customers in accelerating the next generation of scientific discovery and therapeutic innovation. This positions us to deliver compelling strategic and financial benefits for shareholders, customers and employees.”
“For 50 years, Bio-Techne has enabled scientific breakthroughs across proteomics, spatial biology, and novel therapeutics,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “This transaction is a testament to the remarkable company our team has built and to the enduring value we create for our customers and stakeholders. As part of Merck, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact. Together, we will empower our customers to tackle the most important challenges in science and healthcare, helping to improve outcomes worldwide.”
Bio-Techne is one of the leading providers of recombinant proteins, with 50 years of experience in the research and development of innovative technologies and new treatment methods. With Bio-Techne, Merck will expand its portfolio to include a globally established range of cytokines, growth factors, antibodies, and immunoassay kits.
Headquartered in Minneapolis, Minnesota, the company employs more than 3,000 people worldwide, including approximately 2,300 in the US. It has 34 locations and 15 production and manufacturing facilities in the US, Canada, the United Kingdom, Switzerland, and China, and generated revenue of more than $1.2 billion in fiscal year 2025.
